As we are entering cold and flu season, I thought it might be worthwhile to check how popular the latest covid vaccine is.
The press has been keen to report seven million as the number of Americans who have currently received the updated booster.
More than 7 million Americans have received the updated COVID-19 vaccine since it was approved one month ago, according to the Department of Health and Human Services (HHS).The Food and Drug Administration (FDA) signed off on the Pfizer and Moderna shots Sept. 11, and distribution was allowed to begin after the Centers for Disease Control and Prevention (CDC) recommended them Sept. 12.While parents and pediatricians said they’re having problems finding available doses, HHS said 14 million vaccines have shipped to pharmacies and other locations.
However, its declining popularity is being noted by some outlets.
This year’s uptake of the updated Covid-19 vaccine appears to be somewhat slower than last year’s, according to data from the US Department of Health and Human Services and the US Centers for Disease Control and Prevention.More than 7 million Americans have received a dose of the latest vaccines, HHS said Thursday. …In comparison, when last year’s bivalent Covid-19 booster was available, more than 18 million people had received a dose by October 12, 2022, about six weeks after the CDC signed off on it, according to CDC data. By May, about 56.5 million people had received that booster, representing about 17% of the US population.The new Covid-19 vaccines have been updated to target currently circulating coronavirus variants.
Given these numbers, there should be little surprise Big Pharma profits have taken a hit on both news related to the vaccine and treatments developed specifically for battling covid infections.
The US pharmaceutical giant Pfizer sharply scaled back its earnings outlook for the year, blaming lower-than-expected sales of two drugs used to treat Covid-19, the company said Friday.It now “anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion, versus its previous guidance range of $67.0 to $70.0 billion,” Pfizer announced in a statement.Earnings per share – the benchmark for the markets – should come in at between 1.45 and 1.65 dollars, compared with 3.25 to 3.45 dollars previously anticipated.The cut to Pfizer’s guidance was “solely due to its COVID products,” the company said.”Full-year 2023 revenues for Paxlovid and Comirnaty are expected to be approximately $12.5 billion, a decline of $9.0 billion versus original expectations,” it added.
CLICK HERE FOR FULL VERSION OF THIS STORY